Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases;Comparación de la gammagrafía ósea y la 18F-FDG PET-TAC en un paciente con cáncer de próstata con metástasis ósea osteolítica

Revista Espanola de Medicina Nuclear

Volumn 30, Issue 2, 2011, Pages 94-96

  Ozcan Kara, P ^a   Kara, T ^b   Kara Gedik, G ^a   Sari, O ^a   Sahin, O ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b Beyhekim State Hospital   (Turkey)

Author keywords

18F FDG PET CT; Bone metastases; Bone scintigraphy; Prostate cancer

Indexed keywords

CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; ARTICLE; BONE BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; HUMAN; HUMAN TISSUE; ILIAC CREST; INTERMETHOD COMPARISON; LOW BACK PAIN; LUMBAR VERTEBRA; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PATIENT REFERRAL; POSTOPERATIVE PERIOD; PROSTATE CANCER;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; FALSE NEGATIVE REACTIONS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; ILIUM; LUMBAR VERTEBRAE; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; OSTEOLYSIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; SPINAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952901141     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/j.remn.2010.10.008     Document Type: Article

References (11)

1. Surveillance, epidemiology and end results program (). SEER Stat Database 2006. http://www.seer.cancer.gov/.
2. 18F PET. J Nucl Med. 1999, 40:1623-1629.
3. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001, 42:1800-1804.
4. Jacobson A.F., Fogelman I. Bone scanning in clinical oncology: does it have a future?. Eur J Nucl Med. 1998, 25:1219-1223.
5. Hinkle G.H., Burgers J.K., Olsen J.O., Williams B.S., Lamatrice R.A., Barth R.F., et al. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. J Nucl Med. 1998, 39:650-652.
6. Schettino C.J., Kramer E.L., Noz M.E., Taneja S., Padmanabhan P., Lepor H. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol. 2004, 183:519-524.
7. 11C-choline PET/CT for detection of bone metastases. Radiology. 2008, 249:1017-1025.
8. Shreve P.D., Grossmann H.B., Gross M.D., Wahl R.L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-F-18fluoro-D-glucose. Radiology. 1996, 199:751-756.
9. Yeh S.D., Imbriaco M., Larson S.M., Garza D., Zhang J.J., Kalaigian H., et al. Detection of bony metastases of androgen-independent prostate cancerby PET-FDG. Nucl Med Biol. 1996, 23:693-697.
10. 18F-fluoride PET/CT. J Nucl Med. 2006, 47:287-297.
11. Roberts C.C., Daffner R.H., Weissman B.N., Bancroft L., Bennett D.L., Blebea J.S., et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010, 7:400-409.